Biologic mechanisms of oral cancer pain and implications for clinical therapy

Journal of Dental Research

Volumn 91, Issue 5, 2012, Pages 447-453

  Viet, C T ^a,b   Schmidt, B L ^a,b  

^a NEW YORK UNIVERSITY   (United States)

^b NEW YORK UNIVERSITY COLLEGE OF DENTISTRY   (United States)

Author keywords

cancer pain; cancer pain therapy; endogenous opioids; head and neck cancer; opiates; oral cancer

Indexed keywords

ENDOTHELIN 1; NARCOTIC ANALGESIC AGENT; NERVE GROWTH FACTOR; OPIATE PEPTIDE; PROTEINASE ACTIVATED RECEPTOR;

ANALGESIA; ANIMAL; DRUG TOLERANCE; FACE PAIN; GENETICS; HUMAN; INTRACTABLE PAIN; METHODOLOGY; MOUTH TUMOR; NOCICEPTIVE RECEPTOR; PALLIATIVE THERAPY; PATHOPHYSIOLOGY; PHYSIOLOGY; QUALITY OF LIFE; REVIEW; SQUAMOUS CELL CARCINOMA;

ANALGESICS, OPIOID; ANIMALS; CARCINOMA, SQUAMOUS CELL; DRUG TOLERANCE; ENDOTHELIN-1; FACIAL PAIN; HUMANS; MOUTH NEOPLASMS; NERVE GROWTH FACTOR; NOCICEPTORS; OPIOID PEPTIDES; PAIN MANAGEMENT; PAIN, INTRACTABLE; PALLIATIVE CARE; QUALITY OF LIFE; RECEPTORS, PROTEINASE-ACTIVATED;

EID: 84859886082     PISSN: 00220345     EISSN: 15440591     Source Type: Journal    
DOI: 10.1177/0022034511424156     Document Type: Review

References (66)

1. Amadesi S, Cottrell GS, Divino L, Chapman K, Grady EF, Bautista F, et al. Protease-activated receptor 2 sensitizes trpv1 by protein kinase cepsilon- and a-dependent mechanisms in rats and mice. J Physiol. 2006 ; 575 (Pt 2). 555-571 (Pubitemid 44270181)
2. Bernstein MA, Welch SP. Mu-opioid receptor down-regulation and camp-dependent protein kinase phosphorylation in a mouse model of chronic morphine tolerance. Brain Res Mol Brain Res. 1998 ; 55: 237-242 (Pubitemid 28248040)
3. Bhalla S, Matwyshyn G, Gulati A. Endothelin receptor antagonists restore morphine analgesia in morphine tolerant rats. Peptides. 2003 ; 24: 553-561 (Pubitemid 36829344)
4. Bjordal K, Ahlner-Elmqvist M, Hammerlid E, Boysen M, Evensen JF, Biorklund A, et al. A prospective study of quality of life in head and neck cancer patients. Part II: Longitudinal data. Laryngoscope. 2001 ; 111: 1440-1452 (Pubitemid 32730193)
5. Braz J, Beaufour C, Coutaux A, Epstein AL, Cesselin F, Hamon M, et al. Therapeutic efficacy in experimental polyarthritis of viral-driven enkephalin overproduction in sensory neurons. J Neurosci. 2001 ; 21: 7881-7888 (Pubitemid 32952747)
6. Chen SC, Yu WP, Chu TL, Hung HC, Tsai MC, Liao CT. Prevalence and correlates of supportive care needs in oral cancer patients with and without anxiety during the diagnostic period. Cancer Nurs. 2010 ; 33: 280-289
7. Chen Y, Mestek A, Liu J, Yu L. Molecular cloning of a rat kappa opioid receptor reveals sequence similarities to the mu and delta opioid receptors. Biochem J. 1993 ; 295 (Pt 3). 625-628 (Pubitemid 23323479)
8. Connelly ST, Schmidt BL. Evaluation of pain in patients with oral squamous cell carcinoma. J Pain. 2004 ; 5: 505-510 (Pubitemid 39535207)
9. Davar G. Endothelin-1 and metastatic cancer pain. Pain Med. 2001 ; 2: 24-27 (Pubitemid 32454465)
10. Davis BM, Lewin GR, Mendell LM, Jones ME, Albers KM. Altered expression of nerve growth-factor in the skin of transgenic mice leads to changes in response to mechanical stimuli. Neuroscience. 1993 ; 56: 789-792 (Pubitemid 23308636)
11. Di Maio M, Gridelli C, Gallo C, Manzione L, Brancaccio L, Barbera S, et al. Prevalence and management of pain in Italian patients with advanced non-small-cell lung cancer. Br J Cancer. 2004 ; 90: 2288-2296 (Pubitemid 38961890)
12. Epstein JB, Elad S, Eliav E, Jurevic R, Benoliel R. Orofacial pain in cancer: Part II-Clinical perspectives and management. J Dent Res. 2007 ; 86: 506-518
13. Fischer DJ, Villines D, Kim YO, Epstein JB, Wilkie DJ. Anxiety, depression, and pain: differences by primary cancer. Support Care Cancer. 2010 ; 18: 801-810
14. Friedman SM. Optic nerve avulsion secondary to a basketball injury. Ophthalmic Surg Lasers. 1999 ; 30: 676-677 (Pubitemid 29450743)
15. Goss JR, Mata M, Goins WF, Wu HH, Glorioso JC, Fink DJ. Antinociceptive effect of a genomic herpes simplex virus-based vector expressing human proenkephalin in rat dorsal root ganglion. Gene Ther. 2001 ; 8: 551-556 (Pubitemid 32409530)
16. Goss JR, Harley CF, Mata M, O'Malley ME, Goins WF, Hu X, et al. Herpes vector-mediated expression of proenkephalin reduces bone cancer pain. Ann Neurol. 2002 ; 52: 662-665 (Pubitemid 35246874)
17. Guerrero AV, Quang P, Dekker N, Jordan RC, Schmidt BL. Peripheral cannabinoids attenuate carcinoma-induced nociception in mice. Neurosci Lett. 2008 ; 433: 77-81
18. Hans G, Deseure K, Robert D, De Hert S. Neurosensory changes in a human model of endothelin-1 induced pain: a behavioral study. Neurosci Lett. 2007 ; 418: 117-121 (Pubitemid 46635994)
19. Hao S, Hu J, Fink DJ. Transgene-mediated enkephalin expression attenuates signs of naloxone-precipitated morphine withdrawal in rats with neuropathic pain. Behav Brain Res. 2009 ; 197: 84-89
20. Harano N, Ono K, Hidaka K, Kai A, Nakanishi O, Inenaga K. Differences between orofacial inflammation and cancer pain. J Dent Res. 2010 ; 89: 615-620
21. He Y, Yang C, Kirkmire CM, Wang ZJ. Regulation of opioid tolerance by let-7 family microRNA targeting the mu opioid receptor. J Neurosci. 2010 ; 30: 10251-10258
22. Ibrahim MM, Porreca F, Lai J, Albrecht PJ, Rice FL, Khodorova A, et al. Cb2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci USA. 2005 ; 102: 3093-3098 (Pubitemid 40299921)
23. Ibrahim MM, Rude ML, Stagg NJ, Mata HP, Lai J, Vanderah TW, et al. Cb2 cannabinoid receptor mediation of antinociception. Pain. 2006 ; 122: 36-42
24. Kehl LJ, Hamamoto DT, Wacnik PW, Croft DL, Norsted BD, Wilcox GL, et al. A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain. Pain. 2003 ; 103: 175-186 (Pubitemid 36579097)
25. Khodorova A, Fareed MU, Gokin A, Strichartz GR, Davar G. Local injection of a selective endothelin-B receptor agonist inhibits endothelin-1-induced pain-like behavior and excitation of nociceptors in a naloxone-sensitive manner. J Neurosci. 2002 ; 22: 7788-7796 (Pubitemid 35386377)
26. Khodorova A, Navarro B, Jouaville LS, Murphy JE, Rice FL, Mazurkiewicz JE, et al. Endothelin-B receptor activation triggers an endogenous analgesic cascade at sites of peripheral injury. Nat Med. 2003 ; 9: 1055-1061 (Pubitemid 37021786)
27. Kolokythas A, Connelly ST, Schmidt BL. Validation of the University of California San Francisco oral cancer pain questionnaire. J Pain. 2007 ; 8: 950-953 (Pubitemid 350161436)
28. Kolokythas A, Cox DP, Dekker N, Schmidt BL. Nerve growth factor and tyrosine kinase A receptor in oral squamous cell carcinoma: is there an association with perineural invasion?. J Oral Maxillofac Surg. 2010 ; 68: 1290-1295
29. Kosik KS. The neuronal microRNA system. Nat Rev Neurosci. 2006 ; 7: 911-920 (Pubitemid 44780721)
30. Lam DK, Schmidt BL. Serine proteases and protease-activated receptor 2-dependent allodynia: a novel cancer pain pathway. Pain. 2010 ; 149: 263-272
31. Lam DK, Schmidt BL. Orofacial pain onset predicts transition to head and neck cancer. Pain. 2011 ; 152: 1206-1209
32. Law PY, Wong YH, Loh HH. Molecular mechanisms and regulation of opioid receptor signaling. Annu Rev Pharmacol Toxicol. 2000 ; 40: 389-430 (Pubitemid 30340688)
33. Lin YL, Lin IC, Liou JC. Symptom patterns of patients with head and neck cancer in a palliative care unit. J Palliat Med. 2011 ; 14: 556-559
34. Ma J, Jiang Y, Jiang Y, Sun Y, Zhao X. Expression of nerve growth factor and tyrosine kinase receptor A and correlation with perineural invasion in pancreatic cancer. J Gastroen Hepatol. 2008 ; 23: 1852-1859
35. Mague SD, Isiegas C, Huang P, Liu-Chen LY, Lerman C, Blendy JA. Mouse model of oprm1 (a118g) polymorphism has sex-specific effects on drug-mediated behavior. Proc Natl Acad Sci USA. 2009 ; 106: 10847-10852
36. Marshall JA, Mahanna GK. Cancer in the differential diagnosis of orofacial pain. Dent Clin North Am. 1997 ; 41: 355-365
37. Mercadante S, Dardanoni G, Salvaggio L, Armata MG, Agnello A. Monitoring of opioid therapy in advanced cancer pain patients. J Pain Symptom Manage. 1997 ; 13: 204-212 (Pubitemid 27194541)
38. Mercadante S, Fulfaro F, Casuccio A. A randomised controlled study on the use of anti-inflammatory drugs in patients with cancer pain on morphine therapy: effects on dose-escalation and a pharmacoeconomic analysis. Eur J Cancer. 2002 ; 38: 1358-1363 (Pubitemid 34686847)
39. Meunier A, Latremoliere A, Mauborgne A, Bourgoin S, Kayser V, Cesselin F, et al. Attenuation of pain-related behavior in a rat model of trigeminal neuropathic pain by viral-driven enkephalin overproduction in trigeminal ganglion neurons. Mol Ther. 2005 ; 11: 608-616 (Pubitemid 40353118)
40. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993 ; 365: 61-65 (Pubitemid 23305569)
41. Niikura K, Narita M, Butelman ER, Kreek MJ, Suzuki T. Neuropathic and chronic pain stimuli downregulate central mu-opioid and dopaminergic transmission. Trends Pharmacol Sci. 2010 ; 31: 299-305
42. Nyberg P, Ylipalosaari M, Sorsa T, Salo T. Trypsins and their role in carcinoma growth. Exp Cell Res. 2006 ; 312: 1219-1228
43. Oertel BG, Kettner M, Scholich K, Renne C, Roskam B, Geisslinger G, et al. A common human micro-opioid receptor genetic variant diminishes the receptor signaling efficacy in brain regions processing the sensory information of pain. J Biol Chem. 2009 ; 284: 6530-6535
44. Pert CB, Snyder SH. Opiate receptor: demonstration in nervous tissue. Science. 1973 ; 179: 1011-1014
45. Peters CM, Lindsay TH, Pomonis JD, Luger NM, Ghilardi JR, Sevcik MA, et al. Endothelin and the tumorigenic component of bone cancer pain. Neuroscience. 2004 ; 126: 1043-1052 (Pubitemid 38780907)
46. Pickering V, Jay Gupta R, Quang P, Jordan RC, Schmidt BL. Effect of peripheral endothelin-1 concentration on carcinoma-induced pain in mice. Eur J Pain. 2008 ; 123: 293-300 (Pubitemid 351249881)
47. Pickering V, Jordan RC, Schmidt BL. Elevated salivary endothelin levels in oral cancer patients-a pilot study. Oral Oncol. 2007 ; 43: 37-41 (Pubitemid 46162247)
48. Pil J, Tytgat J. Serine 329 of the mu-opioid receptor interacts differently with agonists. J Pharmacol Exp Ther. 2003 ; 304: 924-930 (Pubitemid 36254402)
49. Przewlocki R, Przewlocka B. Opioids in chronic pain. Eur J Pharmacol. 2001 ; 429: 79-91 (Pubitemid 33043984)
50. Quang PN, Schmidt BL. Endothelin-A receptor antagonism attenuates carcinoma-induced pain through opioids in mice. J Pain. 2010a ; 11: 663-671
51. Quang PN, Schmidt BL. Peripheral endothelin B receptor agonist-induced antinociception involves endogenous opioids in mice. Pain. 2010b ; 149: 254-262
52. Ramasubbu C, Gupta A. Pharmacological treatment of opioid-induced hyperalgesia: a review of the evidence. J Pain Palliat Care Pharmacother. 2011 2011 ;:
53. Rigor BM. Pelvic cancer pain. J Surg Oncol. 2000 ; 75: 280-300
54. Russo A, Soh UJ, Trejo J. Proteases display biased agonism at protease-activated receptors: location matters!. Mol Interv. 2009 ; 9: 87-96
55. Saghafi N, Lam DK, Schmidt BL. Cannabinoids attenuate cancer pain and proliferation in a mouse model. Neurosci Lett. 2011 ; 488: 247-251
56. Schmidt BL, Pickering V, Liu S, Quang P, Dolan J, Connelly ST, et al. Peripheral endothelin A receptor antagonism attenuates carcinoma-induced pain. Eur J Pain. 2007 ; 11: 406-414 (Pubitemid 46366762)
57. Schmidt BL, Hamamoto DT, Simone DA, Wilcox GL. Mechanism of cancer pain. Mol Interv. 2010 ; 10: 164-178
58. Sevcik MA, Ghilardi JR, Peters CM, Lindsay TH, Halvorson KG, Jonas BM, et al. Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization. Pain. 2005 ; 115: 128-141
59. Proc Natl Acad Sci USA. Simon EJ Hiller JM Edelman I, ed. 1973: 1947-1949.
60. Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010 ; 363: 733-742
61. Terenius L. Characteristics of the "receptor" for narcotic analgesics in synaptic plasma membrane fraction from rat brain. Acta Pharmacol Toxicol (Copenh). 1973 ; 33: 377-384
62. van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007 ; 18: 1437-1449 (Pubitemid 47365475)
63. Wolfe D, Mata M, Fink DJ. A human trial of HSV-mediated gene transfer for the treatment of chronic pain. Gene Ther. 2009 ; 16: 455-460
64. Wu WD, Wang Y, Fang YM, Zhou HY. Polymorphism of the micro-opioid receptor gene (oprm1 118a>g) affects fentanyl-induced analgesia during anesthesia and recovery. Mol Diagn Ther. 2009 ; 13: 331-337
65. Ye Y, Dang D, Zhang J, Viet CT, Lam DK, Dolan J, et al. Nerve growth factor links oral cancer progression, pain and cachexia. Molecular Cancer Therapeutics. 2011 2011 ;:
66. Zhu Z, Friess H, diMola FF, Zimmermann A, Graber HU, Korc M, et al. Nerve growth factor expression correlates with perineural invasion and pain in human pancreatic cancer. J Clin Oncol. 1999 ; 17: 2419-2428 (Pubitemid 29368241)